The Board of Directors of METabolic EXplorer has five members, appointed by the General Meeting of Shareholders. The Chairman is Benjamin Gonzalez (see Organisation) and the four other members are independent directors. :
Board of Directors
After graduating from ESSEC in 1986, Karin Abadia has held positions of Administrative and Financial Management in various companies in France and abroad (Parsons & Wittemore, Becquet, Eurapharma, Europcar ...). For more than 5 years she has also been responsible for Transition Management, where she is in charge of the reorganization of financial, processing and advisory divisions (Pasteur Institute of Lille, Lorenz Baumer ...). Karin Abadia joined the Board of Directors in 2017.
Daniel Chéron holds a degree in economic sciences from the Université d’Orléans (France). In 1976, he joined Limagrain, an international cooperative group specialised in seeds and grain products, and has spent most of his professional career there. After holding various operational positions, he was appointed Chief Executive Officer of Groupe Limagrain and Coopérative Agricole Limagrain. Mr Chéron was in charge of devising and implementing strategy and oversaw and led the Group's boards of directors (including that of a publicly listed holding company). Since joining the METabolic EXplorer Board of Directors in 2015, Mr Chéron has provided expertise in agro-industry and the diversity of agricultural resources. He is also chairman of the company's audit committee.
Catherine Dunand holds an engineering degree from the Ecole Centrale de Lyon and an MBA from INSEAD. She worked in the pharmaceutical and health sectors for 20 years, including in the Hoechst Marion Roussel group. She manages the Novinvest Partners investment fund and heads Promontoires, a consultancy she founded in 2009. Ms Dunand joined the METabolic EXplorer Board of Directors in 2015.
Jérôme Dupas holds an engineering degree from the Université de Technologie de Compiègne and an MBA from ESSEC business school. He has extensive experience in investment banking in Paris and London. After serving as Managing Director of HSBC Investment Bank in Paris, he was head of Corporate Finance at Fortis and then at BNP Paribas Fortis in France. He is currently Managing Director of Corporate Finance at Pramex International, a subsidiary of the BPCE group. Mr Dupas has participated in the governance of METabolic EXplorer since 2009 and is chairman of its Remuneration and Appointments Committee.
The Board of Directors has created three special committees to serve as supervisory bodies and appointed a censor of the board .
The Strategy Committee examines the company's strategic priorities, reviews information concerning market trends and the competition, and assesses medium- and long-term prospects based on these analyses. It studies any development plans of the company and in particular major investments and proposed industrial partnerships. It has five members: Daniel Chéron (chairman), Benjamin Gonzalez, Catherine Dunand, Jérôme Dupas and Karin Abadia.
The Audit Committee examines the financial statements submitted by the independent auditors and ensures that the accounting methods used to prepare the consolidated and company financial statements are relevant and consistent. The Audit Committee has three independent, non-executive members: Catherine Dunand (chairman), Daniel Chéron and Karin Abadia.
Remuneration and Appointments Committee
The Remuneration and Appointments Committee makes recommendations to the Board of Directors concerning the appointment of Board members, the Chairman of the Board, and the members of its committees. It also recommends the remuneration to be paid to the corporate officers. This committee has two members: Jérôme Dupas (chairman) and Catherine Dunand.
After a 36-year career in the Royal Dutch Shell group, where he held positions in production, sales, marketing and business development and was also in charge of technologies, with national and international responsibilities, Hans Vogelsang served as member of the Board of Directors of METabolic EXplorer from 2008 to 2017. He has also held operational management positions and served on boards of directors in the sectors of petrochemicals, industrial engineering, and industrial services. In 2001 and 2002, he was President of Technology at Basell Polyolefins, and from 2003 to 2013, Senior Independent Non-Executive Director at Bodycote International plc. (LES : BOY). From 2003 to 2006, he was also an advisor for British Sugar. In 2017, Hans Vogelsang has been appointed Censor of the Board of the company.